A microemulsion formulation for inhalation administration

By optimizing the composition and preparation process of the oil and aqueous phases through microemulsion formulation technology, the problems of dissolution and deposition of compound formulations in soft mist devices have been solved, achieving efficient and stable drug delivery and therapeutic effects with low side effects.

CN122297388APending Publication Date: 2026-06-30TIANJIN TIANYAO PHARM CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
TIANJIN TIANYAO PHARM CO LTD
Filing Date
2024-12-30
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively dissolve compound preparations containing inhaled corticosteroids, long-acting anticholinergic drugs, and long-acting β2 receptor agonists in the liquid phase. Furthermore, the compatibility of the delivery device and the aerodynamic particle size parameters of soft aerosol devices are difficult to control, affecting the drug deposition rate in the lungs and the therapeutic effect.

Method used

Microemulsion formulation technology is used to prepare microemulsion formulations containing oil and aqueous phases through high-shear and high-pressure homogenization methods. The composition and emulsion preparation process are optimized to make it suitable for soft mist drug delivery devices, achieving efficient drug deposition in the lungs.

Benefits of technology

This approach achieves high drug deposition rates and low side effects in the lungs, reduces the required treatment dose, and improves the stability and uniformity of drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005216554160000041
    Figure BDA0005216554160000041
  • Figure BDA0005216554160000051
    Figure BDA0005216554160000051
  • Figure BDA0005216554160000052
    Figure BDA0005216554160000052
Patent Text Reader

Abstract

An inhaled microemulsion formulation comprising, as active ingredients, an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β2-receptor agonist, and as excipients, an oil-phase solvent, an emulsifier, an osmotic pressure regulator, a pH buffer, a pH adjuster, a metal ion chelating agent, a bacteriostatic agent, and an aqueous-phase solvent; the inhaled corticosteroid being selected from fluticasone furoate, fluticasone propionate, mometasone furoate, cicsolone, and beclomethasone dipropionate; the long-acting muscarinic antagonist being selected from glycopyrronium bromide, tiotropium bromide, umeclidinium bromide, undilamide bromide, and adecyl bromide; and the long-acting β2-receptor agonist being selected from vilanterol, indacaterol, salmeterol, and formoterol.
Need to check novelty before this filing date? Find Prior Art